 |
|
|
 |
|
Viagra Helps Protect At-Risk Newborns
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 None of the Viagra-treated infants developed rebound pulmonary hypertension compared to 10 of the placebo-treated infants. After more than 24 hours, all of the infants who developed rebound hypertension were given Viagra during a subsequent and successful attempt to wean them from nitric oxide.
The Viagra-treated infants also spent less total time on a mechanical ventilator than the placebo-treated infants -- a little over 28 hours compared to 98 hours -- and had a considerably shorter stay in the intensive care unit (47.8 hours vs. 189 hours).
"Although we expected to see an avoidance of rebound, we were not expecting to see these additional benefits," Shekerdemian said. "Any intervention that smoothes their course in the intensive-care unit would have at least a short-term positive influence on their recovery from their underlying condition."
Text Continues Below

Unless there's some reason for not using Viagra, Shekerdemian said that it should be routinely used as infants are weaned from nitric oxide. "We certainly do so now in our pediatric intensive-care unit," she said.
Many hospitals are already doing just that. "I think it already has become standard clinical practice, because the idea of using Viagra for this is not new," Abman said. "What's new is that this is the first study to look at it with a nice protocol in which they randomized patients and controlled in a blinded way. So it verifies what we've already been doing in clinical practice."
Shekerdemian and her team are now conducting a similar study in the Royal Children's Hospital's Neonatal Intensive-Care Unit to see if Viagra can prevent rebound pulmonary hypertension in premature infants.
More information
There's more on premature newborns at the March of Dimes (www.marchofdimes.com ).
Page: << Prev | 1 | 2
|
Copyright © 2006 ScoutNews, LLC. All rights reserved.
Last updated 11/2/2006
|
 |

SOURCES: Lara Shekerdemian, M.D., Pediatric Intensive Care Unit, The Royal Children's Hospital, Melbourne, Australia; Steven Abman, M.D., professor, Department of Pediatrics, director, Pediatric Heart Lung Center, University of Colorado School of Medicine and The Children's Hospital, Denver; November 2006, American Journal of Respiratory and Critical Care Medicine
|